The Mission Report

Aegis Healthcare Conference

The Wynn, Las Vegas

September 27th - 29th


Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital's management is committed
to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is
focused on enhancing the goals of clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client.
Aegis Capital continues to meet the challenging and changing markets by investing in world-class services such as access to independent
research for its financial advisors and their clients from JP Morgan, Bloomberg, Moody's, Lipper, Best Independent Research LLC,
and Argus Research.

Advanced Cell Technology, Inc. (ACTC)

Advanced Cell Technology, Inc. (OTCBB: ACTC) is a biotech company that specializes in cellular technology in the field of regenerative medicine. The company has three cellular product platforms based on its stem cell technology: Retinal Pigment Epithelial (RPE) therapy for degenerative retinal disease; Mesenchymal Stem Cells (MSCs) from renewable pluripotent stem cell sources; and the Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases. For more information visit the company's Web site at:

Advaxis, Inc. (ADXS)

Advaxis, Inc. (OTC: ADXS) is a clinical-stage biotech company engaged in the development of next generation immunotherapies for cancer and infectious diseases. The company's immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. For more information visit the company's Web site at:

Ampio Pharmaceuticals Inc. (AMPE)

Ampio Pharmaceuticals Inc. (NASDAQ: AMPE) develops innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction. The company's product pipeline includes new uses for previously approved drugs and new molecular entities. Its growth strategy includes actively exploring partnership, licensing and other collaboration opportunities. For more information visit the company's Web site at:

AspenBio Pharma Inc. (APPY)

AspenBio Pharma Inc. (NASDAQ: APPY), an in vitro diagnostic company, focuses on the clinical development and commercialization of its lead product, AppyScore, a blood-based test with projected high sensitivity and negative predictive value that is designed to aid in the identification of patients at low risk for acute appendicitis. AppyScore's initial application is for pediatric, adolescent and young adult patients with abdominal pain. For more information visit the company's Web site at:

AtheroNova Inc. (AHRO)

AtheroNova Inc. (OTCBB: AHRO) is an early-stage biotech company focused on the discovery, research, development and licensing of novel compounds designed to reduce or eliminate atherosclerotic plaque deposits. The company is currently completing two additional studies to validate the efficacy findings of its initial study and prepare for upcoming human trials. AtheroNova plans to develop multiple applications for its compounds. For more information visit the company's Web site at:

BioSpecifics Technologies Corp. (BSTC)

BioSpecifics Technologies Corp. (NASDAQ: BSTC) is the developer of an injectable collagenase, XIAFLEX®, for 12 clinical indications. Currently, XIAFLEX is marketed in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, and is also in clinical development for the treatment of several additional indications. BSTC is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in phase 2 clinical trials. For more information visit the company's Web site at:

Cel-Sci Corp. (CVM)

Cel-Sci Corp. (NYSE: CVM) is focused on the research and development of improvements in the treatment of cancer and other diseases by utilizing the body's immune system. Its lead investigational therapy, Multikine, is currently being studied in a pivotal global phase 3 clinical trial. The company is also developing an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine for Rheumatoid Arthritis using its LEAPS technology platform. The LEAPS drug candidates are currently in preclinical testing. For more information visit the company's Web site at:

Chromadex Corp. (CDXC)

Chromadex Corp. (OTCBB: CDXC) is a natural products company that develops proprietary science-based solutions and ingredients applicable to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company markets and sells its products in the United States and Canada; and sells through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand and Mexico. For more information visit the company's Web site at:

CytRx Corp. (CYTR)

CytRx Corp. (NASDAQ: CYTR) is a biopharm research and development company specializing in the field of oncology. The company's pipeline includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene. The company's third drug candidate, bafetinib, is in the ENABLE phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL). For more information visit the company's Web site at:

FluoroPharma Medical, Inc. (FPMI)

FluoroPharma Medical, Inc. (FPMI) is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. FPMI’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). The company is advancing two products in clinical trials for assessment of acute and chronic forms of coronary disease. For more information visit the company’s Web site at:

Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics Inc. (NASDAQ: GALT) is a development-stage company engaged in developing carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer. GALT also has a colorectal cancer program moving toward commercialization. The company's lead product candidate is a candidate for cancer therapy: GM-CT-01. GR-MD-02 is the company's lead product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis. For more information visit the company's Web site at:

Galena Biopharma Inc. (GALE)

Galena Biopharma Inc. (NASDAQ: GALE) is a biotech company engaged in the discovery, development and commercialization of innovative therapies using targeted biotherapeutics. The company's lead product candidate is NeuVax, which is in phase 3 PRESENT trial for the treatment of various cancers. It also develops Folate Binding Protein-E39, a targeted vaccine that is in phase 1/2 clinical trial for the prevention of recurrence in gynecological cancers. The company was formerly known as RXi Pharmaceuticals Corp. and changed its name to Galena in September 2011.For more information visit the company's Web site at:

IntelGenx Technologies Corp. (IGXT)

IntelGenx Technologies Corp. (OTC: IGXT) is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IGXT has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity. The company's development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, bipolar disorder, idiopathic pulmonary fibrosis, allergies and pain management. For more information visit the company's Web site at:

Invivo Therapeutics Holdings Corp. (NVIV)

Invivo Therapeutics Holdings Corp. (OTCBB: NVIV) is a medical device company that utilizes polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company's products are intended to protect the spinal cord after primary injury by mitigating the bleeding, inflammation, and further cell death that result from the body's immune response to SCI. For more information visit the company's Web site at:

Lpath Inc. (LPTN)

Lpath Inc. (OTC: LPTN) is a biotech company focused on the discovery and development of lipidomic-based therapeutic antibodies for treating human diseases primarily in the United States. LPTN's lead product candidate, iSONEPTM, is currently in two clinical trials to evaluate the safety and potential efficacy for the treatment of Pigment Epithelial Detachment (PED) in wet AMD patients; and a phase 2 study to determine the safety and efficacy of iSONEP given alone or in combination with Lucentis® or Avastin® in subjects with wet Age-related Macular Degeneration (AMD). For more information visit the company's Web site at:

Neuralstem Inc. (CUR)

Neuralstem Inc. (NYSE: CUR) uses its patented technology to produce neural stem cells of the human brain and spinal cord. Neuralstem is in an FDA-approved phase I safety clinical trial for Lou Gehrig's disease, and has been awarded orphan status designation by the FDA; has submitted an IND application for a phase I safety trial in chronic spinal cord injury; and has received FDA approval to conduct a phase Ib safety trial evaluating NSI-189 for the treatment of major depressive disorder (MDD). For more information visit the company's Web site at:

Organovo Holdings Inc. (ONVO)

Organovo Holdings Inc. (OTC: ONVO) is a 3D biology company focused on delivering bioprinting technology and creating tissue on demand for research and medical applications. The company's NovoGen 3D bioprinting technology is a platform that works across all tissue and cell types. ONVO assists pharmaceutical partners in developing human biological disease models in 3D that enable therapeutic drug discovery and development. The company's bioprinting technology can also be developed to create surgical tissues direct therapy. For more information visit the company's Web site at:

PURE Bioscience Inc. (PURE)

PURE Bioscience Inc. (NASDAQ: PURE) develops and markets technology-based bioscience products to address numerous health challenges, including Staph (MRSA). The company's proprietary high efficacy/low toxicity bioscience technologies cater to the consumer use of "green" products while maintaining efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. For more information visit the company's Web site at:

Rosetta Genomics Ltd. (ROSG)

Rosetta Genomics Ltd. (NASDAQ: ROSG) is a molecular diagnostics company that develops and commercializes a range of microRNA-based molecular diagnostic tests. ROSG's product portfolio includes: miRview®lung, miRview®squamos, miRview®meso and miRview®kidney. The company also has a collaboration agreement with the University of California, Davis, to develop and validate a microRNA profile for muscle-invasive bladder cancer. For more information visit the company's Web site at:

SciClone Pharmaceuticals Inc. (SCLN)

SciClone Pharmaceuticals Inc. (NASDAQ: SCLN), a U.S.-based, China-focused specialty pharmaceutical company, markets its product portfolio of differentiated therapies for oncology, infectious diseases and cardiovascular, urological, respiratory and central nervous system disorders. The company's ZADAXIN® is approved in more than 30 countries for the treatment of hepatitis B, hepatitis C and certain cancers. In addition, SCLN markets more than 15 products in China. For more information visit the company's Web site at:

Spectrum Pharmaceuticals Inc. (SPPI)

Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) is a biotech company focused on the acquisition, development and commercialization of drug products, with a primary focus in oncology and hematology. The company markets three oncology drugs: FUSILEV®, for Injection in the U.S.; FOLOTYN®, also marketed in the U.S.; and ZEVALIN® Injection for intravenous use, for which the company has worldwide marketing rights. For more information visit the company's Web site at:

Synergy Pharmaceuticals, Inc. (SGYP)

Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) is developing new drugs to treat gastrointestinal disorders and diseases. Plecanatide, the company's lead proprietary drug candidate, functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in CIC patients. Synergy also initiated dosing of patients in a major Phase II/III clinical trial to treat chronic idiopathic constipation. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases. For more information visit the company's Web site at:

Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals Holding Corp. (OTC: TNXP) is a development-stage specialty pharmaceutical company focused on the development of pharmaceutical products for central nervous system conditions. The company's lead product candidates include TNX-102, for the management of fibromyalgia syndrome; and TNX-105, for the treatment of post-traumatic stress disorder. TNXP's pipeline includes various other product candidates that are under evaluation, such as TNX-201, which is a treatment for certain types of headaches; and TNX-301, a potential treatment for alcohol dependence and addiction. For more information visit the company's Web site at:

TrovaGene Inc. (TROV)

TrovaGene Inc. (NASDAQ: TROV) is the developer of patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine. The company has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. For more information visit the company's Web site at:

VentriPoint Diagnostics Ltd. (VPTDF)

VentriPoint Diagnostics Ltd. (OTC: VPTDF) is a medical device company engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease primarily in Canada and Europe. The company's VentriPoint Diagnostic System is used to generate critical shape and volume measurements of the right ventricle. The VentriPoint Diagnostic System consists of commercial off-the-shelf computer and tracking system sensor, patented and proprietary methods, and software. For more information visit the company's Web site at:


For more frequent updates, follow us on Twitter!

Home     About Us     IR Services     Investors     Partners     Market Research     Blog     Contact     Disclaimer

© 2012 Mission Investor Relations. All rights reserved.
3645 Marketplace Blvd.   Suite 130-280   Atlanta, GA 30344   404-941-8975